ReviewClinical endoscopy2022
Endoscopic treatment for rectal neuroendocrine tumor: which method is better?
Review in Clinical endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- Is salvage treatment necessary after incomplete resection of rectal neuroendocrine tumors: A systematic review and meta-analysis.World journal of gastroenterology · 2026Pooled it
- Predicting Remnant Tumor After Incomplete Resection of Rectal Neuroendocrine Tumors: The KASID Multicenter Retrospective Cohort Study.Journal of gastroenterology and hepatology · 2026Observational
- Comparison between ligation-assisted and precutting endoscopic mucosal resection for small rectal neuroendocrine tumors: a CHASID study.The Korean journal of internal medicine · 2026Article
- Recent updates on the endoscopic treatment of rectal neuroendocrine tumor.Intestinal research · 2026Review
- A rare cause of subepithelial tumor in the rectum.Clinical endoscopy · 2026Article
- Defining endoscopic candidacy for intermediate size rectal neuroendocrine tumors.World journal of gastroenterology · 2026Article
- Redefining therapeutic thresholds and global guidelines: Toward precision management of intermediate-sized rectal neuroendocrine tumors.World journal of gastroenterology · 2025Article
- Long-term outcome of grade 1 rectal neuroendocrine tumor ≤1 cm after incomplete endoscopic resection.Clinical endoscopy · 2025Article
- Long-term outcomes of endoscopic resection of 1-1.5 cm sized grade 1 rectal neuroendocrine tumor: A retrospective study.World journal of gastroenterology · 2025Article
- Metachronous Liver Metastasis during Long-term Follow-up after Endoscopic Submucosal Dissection of a Small Rectal Neuroendocrine Neoplasm.Internal medicine (Tokyo, Japan) · 2025Article
- Submucosal saline injection and mini-probe endoscopic ultrasound to assess endoscopic resectability of colorectal subepithelial tumors.The Korean journal of internal medicine · 2025Article
- Rare Case of Mantle Cell Lymphoma With Multiple Rectal Lesions.United European gastroenterology journal · 2025Article
- A single center retrospective analysis of feasibility of diagnostic endoscopic resection for grade 1 or 2 gastric neuroendocrine tumors.Scientific reports · 2025Article
- Article
- Endoscopic full-thickness resection: A definitive solution for local complete resection of small rectal neuroendocrine neoplasms.World journal of gastroenterology · 2025Article
- Endoscopic resection of rectal neuroendocrine tumors: zero disease-related deaths during a 10-year follow-up period.BMC gastroenterology · 2025Article
- Comparison of endoscopic submucosal dissection and modified endoscopic mucosal resection for rectal neuroendocrine tumors.Scientific reports · 2025Article
- Effective utilization of polypectomy in endoscopic salvage treatment of rectal neuroendocrine tumors: a retrospective cohort study.Annals of surgical treatment and research · 2024Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, research on rectal neuroendocrine tumors (NETs) has increased during the last few decades. Rectal NETs measuring <10 mm without atypical features and confined to the submucosal layer have only 1% risk of metastasis, and the long-term survival probability of patients without metastasis at the time of diagnosis is approximately 100%. Therefore, the current guidelines suggest endoscopic resection of rectal NETs of <10 mm is regarded as a safe therapeutic option. However, there are currently no clear recommendations for technique selection for endoscopic resection. The choice of treatment modality for rectal NETs should be based on the lesion size, endoscopic characteristics, grade of differentiation, depth of vertical involvement, lymphovascular invasion, and risk of metastasis. Moreover, the complete resection rate, complications, and experience at the center should be considered. Modified endoscopic mucosal resection is the most suitable resection method for rectal NETs of <10 mm, because it is an effective and safe technique that is relatively simple and less time-consuming compared with endoscopic submucosal dissection. Endoscopic submucosal dissection should be considered when the tumor size is >10 mm, suctioning is not possible due to fibrosis in the lesion, or when the snaring for modified endoscopic mucosal resection does not work well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.